



## Prior Authorization Criteria

---

### JUXTAPID® (lomitapide) PA CRITERIA:

*For use as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with **homozygous familial hypercholesterolemia (HoFH)***

Juxtapid may be approved based on ALL of the following criteria:

#### **INITIAL AUTHORIZATION: 6 months**

Yes  No Age of patient is within the age of the FDA label; **AND**

Yes  No Prescribed by or in consultation with a cardiologist, endocrinologist, or lipid specialist; **AND**

Yes  No Diagnosis of Homozygous Familial Hypercholesterolemia (HoFH), based on the presence of the following:

- Genetic confirmation of two mutant alleles at the LDLR, ApoB, PCSK9, or LDLRAP1 gene locus

**OR**

- Treated LDL-C of > 300 mg/dL **OR** untreated LDL-C of > 500 mg/dL;

**AND**

Yes  No **ONE** of the following:

- Cutaneous or tendon xanthoma before age 10 years; **OR**
- Evidence of heterozygous familial hypercholesterolemia in both parents such as:

- LDL > than 190 mg/dL or TC > 310mg/dL

**or**

- Premature ASCVD (before age 55 men; before age 60 women)

**or**

- Sudden premature cardiac death

**or**

- Tendon xanthoma

**AND**

Yes  No History of intolerance, failure or contraindication to Repatha (evolocumab);

**AND**

Yes  No Patient is receiving other lipid-lowering therapy (e.g., statin, ezetimibe, LDL apheresis); **AND**

Yes  No Not used in combination with a PCSK-9 Inhibitor.

**REAUTHORIZATION: 12 months**

Yes  No Prescribed by or in consultation with a cardiologist, endocrinologist, or lipid specialist; **AND**

Yes  No Patient is adherent to and will continue a low-fat diet and exercise regimen; **AND**

Yes  No Submission of medical records (e.g. chart notes, laboratory values) upon request documenting maintenance of LDL-C reduction while on Juxtapid therapy); **AND**

Yes  No Patient does not have any contraindications to therapy; **AND**

Yes  No Not used in combination with a PCSK9 inhibitor; **AND**

Yes  No If appropriate, beneficiary continues to receive other lipid-lowering therapy (e.g., statin, ezetimibe, LDL apheresis, etc.).

**Juxtapid Product Availability:**

- Capsules 5mg, 10mg, 20mg, 30mg, 40mg, and 60 mg